Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
---|---|---|---|---|
Sengupta S et al. | 2018 | intact cell/cell culture, HCT116 cells (colorectal cancer cells) and human hepatocarcinoma cell line (HepG2) | static magnetic field, co-exposure, also other exposures without EMF | - |
Yang X et al. | 2020 | intact cell/cell culture, HCT116 cells (colorectal cancer cells), A549 (human adenocarcinoma cell line), LoVo cells | static magnetic field, co-exposure | - |
Hwang J et al. | 2023 | intact cell/cell culture, HEK 293T cells (human embryonic kidney cells), C2C12 cells (undifferentiated mouse myoblasts) and satellite cells, animal, C57BL/6J mouse | static magnetic field | - |
El-Gaddar A et al. | 2013 | intact cell/cell culture, HEK cells (human embryonic kidney cells) and yeast cells (<i>Saccharomyces cerevisiae</i>) | static magnetic field | 0.5 T |
Obayashi-Ishii M et al. | 2018 | intact cell/cell culture, HSC-3 cells (human oral squamous cell carcinoma) | static magnetic field | - |
Gurhan H et al. | 2021 | intact cell/cell culture, HT-1080 (fibrosarcoma cells) | static magnetic field | - |
Bajtoš M et al. | 2024 | intact cell/cell culture, HT-1080 (fibrosarcoma cells) | static magnetic field, magnetic field, 50/60 Hz, co-exposure | - |
Castello PR et al. | 2014 | intact cell/cell culture, HT1080 cells (human fibrosarcoma cell line) | RF, magnetic field, static magnetic field, co-exposure | - |
Gurhan H et al. | 2018 | intact cell/cell culture, HT1080 cells (human fibrosarcoma cell line) | static magnetic field | - |
Raylman RR et al. | 1996 | intact cell/cell culture, HTB 63 (melanoma cells), HTB 77 IP3 (ovarian carcinoma cells) and CCL 86 (lymphoma cells) | static magnetic field | 7 T |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.